Stephen Liu flagged the final Phase III SKYSCRAPER-01 readout in JCO: adding the anti-TIGIT antibody tiragolumab to atezolizumab did not significantly improve PFS or OS in first-line PD-L1-high NSCLC, despite an encouraging Phase II. The miss reopened KOL debate over whether the TIGIT class can translate — and whether differently engineered, Fc-active anti-TIGIT antibodies might still succeed.
“Phase III SKYSCRAPER-01 @JCO_ASCO: 1L atezolizumab +/- tiragolumab (anti-TIGIT) for PDL1 high NSCLC (n=521). Adding tiragolumab did not significantly improve PFS (7m vs 5.6m, HR 0.78, ns) or OS (23.1m vs 16.9m, HR 0.87, ns), despite promising phase II.”
— @StephenVLiu · SKYSCRAPER-01 · View post ↗
“The TIGIT chapter is becoming a story to learn. So far it has been mostly of Ph3 failing the ph2 promises. Now, differently designed TIGITS may change it. Fc-mediated differences in T cells might be the dealbreaker. Do you see any encouraging signs with donvalanimab?”
— @mgonzalezvelMD · Anti-TIGIT Class · View post ↗Advocacy is growing for early screening for brain metastases in advanced TNBC and HER2+ breast cancer, given the availability of effective therapies for CNS disease. New publications include a 5-year quality of life study from the SUPREMO trial, which examined chest wall radiotherapy in intermediate-risk breast cancer. Additionally, a prospective study in early breast cancer linked greater adiposity with worse diastolic function.
“In advanced #TNBC and #Her2+ breast cancer, for many it’s not an “if”brain metastases will occur, it’s a “when.” Catching brain disease early can preserve cognitive function and decrease rates of catastrophic complications (herniation/death).”
— @Dr_RShatsky · Brain Metastases Screening · View post ↗📌 Amplified by @KolPulseAI
“Brain imaging screening in #MetastaticBreastCancer: Is it time to rethink clinical guidelines and practice? In this recent editorial Drs. Sarah Sammons, Nayan Lamba and Nancy Lin present some compelling reasons: 🔦Screening for #BrainMetastasis (BM) is associated with clinically relevant rates of detection of asymptomatic disease 🔦Screening for #BrainMets leads to diagnosis of smaller and fewer lesions, prior to the development of neurologic symptoms 🔦Advanced radiation oncology techniques are safer and more effective for smaller #CNS system lesions 🔦Treating patients with asymptomatic/occult lesions may result in better outcomes 🔦Advances in systemic treatments have expanded treatment options and improved outcomes for patients with BM, particularly in HER2+ #MBC 🔦The identification of asymptomatic BM on brain imaging scans can lead to changes in treatment strategy.”
— @DFCI_BreastOnc · Brain Metastases Screening · View post ↗
“This month's podcast: 5-year QoL study of the SUPREMO trial examining chest wall RT in patients with intermediate-risk breast cancer with Prof Galina Velikova”
— @TheLancetOncol · SUPREMO Trial · View post ↗
“In our prospective study with longitudinal echos, greater adiposity was associated with worse diastolic function, in EBC.”
— @chefaleixomd · Cardio-Oncology · View post ↗A randomized phase II trial is underway for newly diagnosed stage IV metastatic colorectal cancer (mCRC) patients without liver metastases, evaluating chemotherapy plus the investigational PD-1/CTLA-4 bispecific antibody volrustomig. Other discussions recapped existing topics in gastric and gastroesophageal cancers, including the FLOT plus durvalumab regimen and biomarker-guided treatments.
“For newly diagnosed stage IV mCRC patients w/o liver mets there is a randomized phase II chemotherapy + bispecific combo of PD-1/CTLA-4 (Volrustomig) #immunotherapy trial underway @AstraZeneca.”
— @CathyEngMD · Volrustomig in mCRC · View post ↗📌 Amplified by @KolPulseAI
“Covered: multidisciplinary care, FLOT+durvalumab, biomarker-guided treatment(MSI, PD-L1, HER2, Claudin 18.2)&more.”
— @JaruratCare · Gastric Cancer Topics · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The RADICAL (A031801) trial found that adding radium-223 to cabozantinib did not improve symptomatic skeletal event-free survival in patients with metastatic RCC and bone metastases. In urothelial cancer, retrospective data for patients progressing on enfortumab vedotin plus pembrolizumab showed a 49% ORR to second-line platinum chemotherapy, with a median duration of response of 5.2 months. Additionally, a UNITE Consortium study demonstrated prognostic value for longitudinal ctDNA monitoring during EV ± pembrolizumab therapy.
“In conclusion, the addition of radium-223 to cabozantinib did not improve symptomatic skeletal event-free survival in patients with metastatic RCC and bone metastases.”
— @DrChoueiri · RADICAL trial results · View post ↗
“📈 ORR 49% to second-line platinum, including 2 complete responses 🔍 Median DOR 5.2 months, median PFS 5 months, median OS 12 months 📊 No difference between cisplatin and carboplatin (P > 0.9)”
— @katy_beckermann · Platinum chemo post-EV+pembrolizumab · View post ↗
“Longitudinal, tumor-informed ctDNA monitoring during EV ± pembrolizumab provides important prognostic insights and represents another step toward biomarker-driven care in advanced urothelial carcinoma.”
— @niklas_kluemper · ctDNA in urothelial cancer · View post ↗A key discussion highlights how commercial FISH panel design may create a perception that certain trisomies (+5, +9, +15) are most common in multiple myeloma, emphasizing that these screening assays are not comprehensive genomic maps. Separately, the myeloma/hematology community is revisiting the ENDURANCE trial to discuss the standard of care for maintenance therapy duration.
“WHY do +5, +9, and +15 seem to be the most common trisomies in multiple myeloma? The answer may have as much to do with assay design as with biology.”
— @HenrychihangFu1 · Trisomy Assay Design · View post ↗“ASSAY DESIGN ≠ BIOLOGY A screening panel is not the genome.”
— @HenrychihangFu1 · Genomic Testing · View post ↗
“In our ongoing Multiple Myeloma series we had a chance to 🗣️ #ENDURANCE trial w/ @myelomaMD & @VincentRK ✅ New SoC duration for Maintenance ✅ Can we extrapolate to other pts?”
— @OncBrothers · ENDURANCE Trial · View post ↗The phase III MATRix/IELSG43 trial, comparing high-dose chemotherapy with autologous stem-cell transplantation against non-myeloablative consolidation for primary CNS lymphoma, has been published in The Lancet. A detailed clinical guide to fludarabine use in allo-HSCT is also being shared, outlining dosing for MAC, RIC, and NMA conditioning and highlighting critical precautions for renal impairment and neurotoxicity, including dose adjustments based on CrCl.
“High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial - The Lancet”
— @MostafaFaisal14 · MATRix/IELSG43 trial · View post ↗
“Conditioning intensity is determined mainly by the partner agent/dose—not fludarabine alone.”
— @abouabdrahman0 · Fludarabine in allo-HSCT · View post ↗“Fludarabine’s active metabolite is substantially renally eliminated.”
— @abouabdrahman0 · Fludarabine precautions · View post ↗
“MSAC approved NGS as both clinically- + cost-effective for haematology patients - so why is NGS still inaccessible for many?”
— @Eddie_Cliff · NGS access in Australia · View post ↗